Skip to content

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.

Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily C. Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Tatiana Son, Norman A. S. Farb, Rotem Petranker

BJPsych Open May 13, 2026 DOI: 10.1192/bjo.2026.12000 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Corrigendum Randomized Placebo-controlled Double-blind Peer reviewed
Population Major depressive disorder
Topics Depression Microdosing Psilocybin
Key points This is a corrigendum to a study protocol for microdosing psilocybin for MDD; no results.

Abstract

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.

Related reading